See more : Advance Lithium Corp. (AAX.V) Income Statement Analysis – Financial Results
Complete financial analysis of Rani Therapeutics Holdings, Inc. (RANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rani Therapeutics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- RDE, Inc. (RSTN) Income Statement Analysis – Financial Results
- Atresmedia Corporación de Medios de Comunicación, S.A. (AIOSF) Income Statement Analysis – Financial Results
- Jinan High-tech Development Co., Ltd. (600807.SS) Income Statement Analysis – Financial Results
- Murphy Canyon Acquisition Corp. (MURF) Income Statement Analysis – Financial Results
- USERJOY Technology Co.,Ltd. (3546.TWO) Income Statement Analysis – Financial Results
Rani Therapeutics Holdings, Inc. (RANI)
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.72M | 462.00K | 979.00K |
| Cost of Revenue | 822.00K | 1.31M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -822.00K | -1.31M | 2.72M | 462.00K | 979.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 39.62M | 36.61M | 26.48M | 12.04M | 24.58M |
| General & Administrative | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.48M | 26.84M | 27.83M | 4.96M | 3.47M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Cost & Expenses | 66.10M | 63.45M | 54.32M | 17.01M | 28.04M |
| Interest Income | 3.30M | 1.25M | 89.00K | 63.00K | 423.00K |
| Interest Expense | 5.09M | 1.07M | 466.00K | 124.00K | 10.00K |
| Depreciation & Amortization | 822.00K | 1.31M | 497.00K | 589.00K | 564.00K |
| EBITDA | -65.28M | -60.89M | -52.08M | -15.96M | -26.01M |
| EBITDA Ratio | 0.00% | 0.00% | -1,895.84% | -3,439.83% | -2,663.74% |
| Operating Income | -66.10M | -63.45M | -51.60M | -16.54M | -27.07M |
| Operating Income Ratio | 0.00% | 0.00% | -1,899.12% | -3,580.95% | -2,764.56% |
| Total Other Income/Expenses | -1.78M | 177.00K | -1.45M | -124.00K | 478.00K |
| Income Before Tax | -67.88M | -63.27M | -53.05M | -16.67M | -26.59M |
| Income Before Tax Ratio | 0.00% | 0.00% | -1,952.41% | -3,607.79% | -2,715.73% |
| Income Tax Expense | 0.00 | 70.00K | 41.00K | 35.00K | 10.00K |
| Net Income | -33.97M | -63.34M | -53.09M | -16.70M | -26.60M |
| Net Income Ratio | 0.00% | 0.00% | -1,953.92% | -3,615.37% | -2,716.75% |
| EPS | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| EPS Diluted | -1.33 | -2.66 | -2.69 | -0.85 | -1.35 |
| Weighted Avg Shares Out | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
| Weighted Avg Shares Out (Dil) | 25.51M | 23.82M | 19.71M | 19.74M | 19.74M |
Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates
Rani Therapeutics to Present at Upcoming Investor Conferences
Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
Rani Therapeutics Holdings, Inc. (RANI) Talat Imran on Q4 2021 Results - Earnings Call Transcript
Rani Therapeutics to Release Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 29, 2022
This Recent Biologics IPO Could Be Heading Toward a Gain of 60% or More
Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference
Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update
Wednesday Afternoon Analyst Upgrades and Downgrades: Applied Materials, Best Buy, Intuit, Medtronic, Toll Brothers and More
Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA
Source: https://incomestatements.info
Category: Stock Reports